NasdaqGM:ADMABiotechs
A Look At ADMA Biologics (ADMA) Valuation After Analyst Downgrades And Channel Stuffing Allegations
ADMA Biologics (ADMA) is back in focus after recent analyst downgrades tied to allegations of Asceniv revenue channel stuffing, rising days' sales outstanding and accounts receivable, and criticism of the company’s public response.
See our latest analysis for ADMA Biologics.
The recent short report and analyst downgrades come after a difficult stretch for ADMA’s share price, with a 30 day share price return of a 24.02% decline and a year to date share price return of a 39.15% decline, even...